Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.350
Sell
RSI(14)
50.361
Neutral
STOCH(KDJ)(9,3,3)
49.339
Buy
ATR(14)
1.351
High Vlolatility
CCI(14)
23.199
Neutral
Williams %R
34.015
Buy
TRIX(12,20)
-0.234
Sell
StochRSI(14)
100.000
Overbought
Vericel Corp
VCEL37.370USD
+1.320+3.66%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
1.89BMarket Cap
137.13P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Vericel Corp
Currency: USD Updated: 2025-12-22Key Insights
Vericel Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 43/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 55.71.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vericel Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Buy
Current Rating
55.714
Target Price
+49.37%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Vericel Corp Highlights
StrengthsRisks
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 44.33% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 137.13, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 54.99M shares, decreasing 7.98% quarter-over-quarter.
Held by Ken Fisher
Star Investor Ken Fisher holds 169.61K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-22The current financial score of Vericel Corp is 9.35, ranking 5/158 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 67.50M, representing a year-over-year increase of 16.58%, while its net profit experienced a year-over-year increase of 663.15%.
Score
Financials
9.04
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.71
Vericel Corp's Company Valuation
Currency: USD Updated: 2025-12-22The current valuation score of Vericel Corp is 5.14, ranking 152/158 in the Pharmaceuticals industry. Its current P/E ratio is 137.13, which is 3378.43% below the recent high of 4770.06 and 670.75% above the recent low of -782.68.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 43/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-22The current earnings forecast score of Vericel Corp is 8.50, ranking 28/158 in the Pharmaceuticals industry. The average price target for Vericel Corp is 55.00, with a high of 62.00 and a low of 50.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
55.714
Target Price
+49.37%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Vericel Corp
VCEL
8
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-22The current price momentum score of Vericel Corp is 7.03, ranking 96/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 41.77 and the support level at 33.88, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
36.296
Buy
MA10
36.792
Buy
MA20
37.707
Sell
MA50
37.355
Buy
MA100
35.631
Buy
MA200
38.756
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-22The current institutional shareholding score of Vericel Corp is 10.00, ranking 1/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 108.73%, representing a quarter-over-quarter decrease of 4.19%. The largest institutional shareholder is The Vanguard, holding a total of 3.50M shares, representing 6.93% of shares outstanding, with 0.18% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
William Blair Investment Management, LLC
Conestoga Capital Advisors, LLC
Brown Capital Management, LLC
Geneva Capital Management LLC
Congress Asset Management Company, LLP
Fidelity Management & Research Company LLC
GW&K Investment Management, LLC
1
2
Risk Assessment
Currency: USD Updated: 2025-12-22The current risk assessment score of Vericel Corp is 5.78, ranking 63/158 in the Pharmaceuticals industry. The company's beta value is 1.18. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.18
VaR
+5.10%
240-Day Maximum Drawdown
+51.72%
240-Day Volatility
+52.68%
Return
Best Daily Return
60 days
+9.41%
120 days
+9.41%
5 years
+26.97%
Worst Daily Return
60 days
-5.29%
120 days
-14.07%
5 years
-23.43%
Sharpe Ratio
60 days
+2.25
120 days
-0.14
5 years
+0.19
Risk Assessment
Maximum Drawdown
240 days
+51.72%
3 years
+51.72%
5 years
+73.97%
Return-to-Drawdown Ratio
240 days
-0.69
3 years
+0.18
5 years
-0.06
Skewness
240 days
+0.19
3 years
+0.18
5 years
+0.50
Volatility
Realised Volatility
240 days
+52.68%
5 years
+55.18%
Standardised True Range
240 days
+5.22%
5 years
+5.18%
Downside Risk-Adjusted Return
120 days
-20.46%
240 days
-20.46%
Maximum Daily Upside Volatility
60 days
+42.57%
Maximum Daily Downside Volatility
60 days
+25.75%
Liquidity
Average Turnover Rate
60 days
+1.07%
120 days
+1.06%
5 years
--
Turnover Deviation
20 days
+18.34%
60 days
+19.78%
120 days
+18.68%
Peer Comparison
Pharmaceuticals
Vericel Corp
VCEL
7.79 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.71 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Vericel Corp?
The TradingKey Stock Score provides a comprehensive assessment of Vericel Corp based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Vericel Corp’s performance and outlook.
How do we generate the financial health score of Vericel Corp?
To generate the financial health score of Vericel Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Vericel Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Vericel Corp.
How do we generate the company valuation score of Vericel Corp?
To generate the company valuation score of Vericel Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Vericel Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Vericel Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Vericel Corp.
How do we generate the earnings forecast score of Vericel Corp?
To calculate the earnings forecast score of Vericel Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Vericel Corp’s future.
How do we generate the price momentum score of Vericel Corp?
When generating the price momentum score for Vericel Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Vericel Corp’s prices. A higher score indicates a more stable short-term price trend for Vericel Corp.
How do we generate the institutional confidence score of Vericel Corp?
To generate the institutional confidence score of Vericel Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Vericel Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Vericel Corp.
How do we generate the risk management score of Vericel Corp?
To assess the risk management score of Vericel Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Vericel Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Vericel Corp.
